GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sequent Scientific Ltd (NSE:SEQUENT) » Definitions » Price-to-Owner-Earnings

Sequent Scientific (NSE:SEQUENT) Price-to-Owner-Earnings : (As of Jun. 01, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Sequent Scientific Price-to-Owner-Earnings?

As of today (2025-06-01), Sequent Scientific's share price is ₹191.84. Sequent Scientific does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sequent Scientific's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Sequent Scientific was 133.79. The lowest was 3.53. And the median was 64.00.


NSE:SEQUENT's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.175
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-06-01), Sequent Scientific's share price is ₹191.84. Sequent Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.85. Therefore, Sequent Scientific's PE Ratio (TTM) for today is 225.69.

As of today (2025-06-01), Sequent Scientific's share price is ₹191.84. Sequent Scientific's EPS without NRI for the trailing twelve months (TTM) ended in was ₹0.84. Therefore, Sequent Scientific's PE Ratio without NRI for today is 228.38.

During the past 13 years, Sequent Scientific's highest PE Ratio without NRI was 2442.13. The lowest was 21.49. And the median was 62.45.


Sequent Scientific Price-to-Owner-Earnings Historical Data

The historical data trend for Sequent Scientific's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequent Scientific Price-to-Owner-Earnings Chart

Sequent Scientific Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 110.50 - - - -

Sequent Scientific Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sequent Scientific's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sequent Scientific's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequent Scientific's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sequent Scientific's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sequent Scientific's Price-to-Owner-Earnings falls into.


;
;

Sequent Scientific Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sequent Scientific's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=191.84/-1.10
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequent Scientific  (NSE:SEQUENT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sequent Scientific Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sequent Scientific's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequent Scientific Business Description

Traded in Other Exchanges
Address
Plot No. E7, Road No. 22, 301, 3rd Floor, Dosti Pinnacle, Wagle Industrial Estate, Thane (West), Mumbai, MH, IND, 400 604
Sequent Scientific Ltd is a pharmaceutical company operating animal health and analytical services. It develops API products and formulations. The company's product portfolio includes products across various therapy classes such as antibiotics, anthelmintics, pain management, and nutrition. The company's geographical segment includes Europe, Asia, and Rest of the world. It generates maximum revenue from Europe.

Sequent Scientific Headlines

No Headlines